1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Celebrity Takes Role In US FDA Study Of Rx Drug Endorsements

 
• By Brenda Sandburg

Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.

Photographers are taking a picture of a film star
FDA to study impact of celebrity endorsements of Rx drug products

The US Food and Drug Administration is casting a celebrity for a study to assess the influence an endorser's status has on viewer perceptions of direct-to-consumer (DTC) prescription drug advertising.

The agency said it is not disclosing the identity of the individual in order to maintain the integrity of the research process. But a description of the proposed research, which will also examine whether payment disclosure has an impact, notes that it is someone who has publicly spoken out about acne

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.